As at 28 June 2021, the number of shares in issue was 25,871,612. The company does not hold any ordinary shares in treasury.
At 23 June 2021, the Company has been notified of the following interests in 3% or more of the issued ordinary share capital of the Company:
|Shareholder||No. of ordinary shares||% of issued share capital|
|Invest Northern Ireland||3,197,865||12.39|
|Amati Global Investors Limited||2,341,463||9.07|
|Viridian Growth Fund LP||1,831,500||7.09|
|Octopus Investments Limited||1,525,258||5.91|
|Hargreave Hale Limited||1,402,439||5.43|
|Livingbridge VC LLP||1,219,512||4.72|
|Unicorn AIM VCT plc||1,219,512||4.72|
|Director||No. of ordinary shares||% of issued share capital|
|Dr Richard John Buick||611,250||2.37|
|Dr Simon Gordon Douglas||255,800||0.99|
|Dr Alan Mawson 1||124,000||0.48|
|Sonya Maria Ferguson||67,567||0.26|
|Timothy William Watts||27,575||0.11|
|Colin James Walsh 2||-||-|
|James Alexander Fair||-||-|
(1) Alan Mawson is a non-executive director of Clarendon Fund Managers Limited ("Clarendon") and sits on Clarendon's investment committee. Clarendon
is the fund manager for Nitech Growth Fund LP which holds 358,850 Ordinary Shares and Viridian Growth Fund LP which holds 1,831,500 Ordinary Shares.
(2) Colin Walsh is the Chief Executive and founder of Crescent Capital NI Limited, which is the fund manager for Crescent Capital II LP and Crescent Capital III LP which hold 2,652,325 Ordinary Shares and 731,707 Ordinary Shares respectively.
Insofar as it is aware, as at 26 May 2021, 23.68% of the Company's securities is not in public hands.
The rights of shareholders are governed by UK law.
There are no restrictions on the transfer of the Company's ordinary shares.
The Company is subject to the provisions of the City Code on Takeover and Mergers.
Fusion Antibodies has not applied or agreed to have any of its securities admitted or traded on any other exchanges or trading platforms.
Page last updated: 29 June 2021